Evofem Biosciences Statistics
Want to see EVFM full AI Analyst Report?
Evofem Biosciences (EVFM) Stock Statistics & Valuation Metrics
Total Valuation
Evofem Biosciences has a market cap or net worth of $808.43K. The enterprise value is $60.16M.
- Market Cap
- $808.43K
- Enterprise Value
- $60.16M
Share Statistics
Evofem Biosciences has 132,530,080 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 132,530,080
- Owned by Insiders
- ―
- Owned by Institutions
- <0.01%
Financial Efficiency
Evofem Biosciences’s return on equity (ROE) is -0.01 and return on invested capital (ROIC) is -14.24%.
- Return on Equity (ROE)
- -0.01
- Return on Assets (ROA)
- 0.02
- Return on Invested Capital (ROIC)
- -14.24%
- Return on Capital Employed (ROCE)
- -0.02
- Revenue Per Employee
- 695.97K
- Profits Per Employee
- 13.48K
- Employee Count
- 29
- Asset Turnover
- 1.00
- Inventory Turnover
- 4.53
Valuation Ratios
The current PE Ratio of Evofem Biosciences is -0.07. Evofem Biosciences’s PEG ratio is -0.00.
- PE Ratio
- -0.07
- PS Ratio
- 0.06
- PB Ratio
- -0.01
- Price to FCF
- -1.37
- Price to Operating Cash Flow
- -1.43
- PEG Ratio
- -0.00
Income Statement
In the last 12 months, Evofem Biosciences had revenue of 20.18M and earned 391.00K in profits. Earnings per share was 0.00.
- Revenue
- 20.18M
- Gross Profit
- 15.07M
- Operating Income
- 1.44M
- Pretax Income
- 393.00K
- Net Income
- 391.00K
- EBITDA
- 2.06M
- Earnings Per Share (EPS)
- 0.00
Cash Flow
In the last 12 months, operating cash flow was -472.00K and capital expenditures -5,000, giving a free cash flow of -477.00K billion.
- Operating Cash Flow
- -472.00K
- Free Cash Flow
- -477.00K
- Free Cash Flow per Share
- -0.00
Dividends & Yields
Evofem Biosciences pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -58.05%
- Earnings Yield
- -1797.08%
Stock Price Statistics
- Beta
- 0.33
- 52-Week Price Change
- 0.00%
- 50-Day Moving Average
- 0.01
- 200-Day Moving Average
- 0.01
- Relative Strength Index (RSI)
- ―
- Average Volume (3m)
- ―
Important Dates
Evofem Biosciences upcoming earnings date is Mar 04, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 12, 2026
- Next Earnings Date
- Mar 04, 2027
- Ex-Dividend Date
- ―
Financial Position
Evofem Biosciences as a current ratio of 0.18, with Debt / Equity ratio of -78.56%
- Current Ratio
- 0.18
- Quick Ratio
- 0.17
- Debt to Market Cap
- 46.28
- Net Debt to EBITDA
- 26.14
- Interest Coverage Ratio
- 0.55
Taxes
In the past 12 months, Evofem Biosciences has paid 2,000 in taxes.
- Income Tax
- 2,000
- Effective Tax Rate
- 0.01
Enterprise Valuation
Evofem Biosciences EV to EBITDA ratio is -16.02, with an EV/FCF ratio of -144.73.
- EV to Sales
- 3.83
- EV to EBITDA
- -16.02
- EV to Free Cash Flow
- -144.73
- EV to Operating Cash Flow
- -146.26
Balance Sheet
Evofem Biosciences has $285.00K in cash and marketable securities with $68.50M in debt, giving a net cash position of -$68.22M billion.
- Cash & Marketable Securities
- $285.00K
- Total Debt
- $68.50M
- Net Cash
- -$68.22M
- Net Cash Per Share
- -$0.51
- Tangible Book Value Per Share
- -$0.61
Margins
Gross margin is 69.29%, with operating margin of -22.71%, and net profit margin of -98.28%.
- Gross Margin
- 69.29%
- Operating Margin
- -22.71%
- Pretax Margin
- -97.08%
- Net Profit Margin
- -98.28%
- EBITDA Margin
- -20.66%
- EBIT Margin
- -28.36%
Analyst Forecast
The average price target for Evofem Biosciences is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- 4.49%
- EPS Growth Forecast
- -89.40%
Scores
- Smart Score
- ―
- AI Score
- 44
